Mieloproliferatív neopláziák: vizsgálatok itt: Horvátország
3 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleAdding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
- Where
- Grad Zagreb, Rijeka, Šibenik, Split, Zagreb
- Életkor
- 18 év and over
- People
- 126 worldwide
- Run by
- Kartos Therapeutics Inc.
See details and how to join2023-504724-25-00 - 3. fázisFut, nem toborozStudy on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
- Where
- Grad Zagreb, Rijeka, Šibenik
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Italfarmaco
See details and how to joinNCT06093672 · EU 2022-502276-23-00 - 3. fázisTaking peopleStudy of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Where
- Rijeka, Šibenik, Split, Zagreb
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT06479135